Pharmacovigilance experts from around the globe gather in Uppsala to discuss the latest advances as well as challenges in the field of medicines safety.
Uppsala Forum is an invite-only research conference, gathering pharmacovigilance experts from notable organisations across the globe for cutting-edge debates on new directions of research in pharmacovigilance.
The Forum that was planned for 2020, which was initially postponed until 2021, had to be cancelled completely. At present, there are no firm plans for a subsequent Forum, but any such event will be advertised here in the future.
The edition of Uppsala Forum that was initially planned for 2020 was postponed until 2021 due to COVID-19, but had to be completely cancelled in the end.
In 2018, Uppsala Forum was replaced by UMC’s 40th Anniversary conference, where key actors from the past and present of the WHO Programme for International Drug Monitoring joined pharmacovigilance colleagues to reflect on the progress pharmacovigilance has made since the programme’s inception in 1968.
The need to develop and rapidly deploy new treatments tests the limits of traditional pharmacovigilance and demands new thinking and practice. How can we ensure the safety of patients using new drugs when rapid access is of paramount importance?
Topics covered included: Patient groups at risk – genotypes and phenotypes; Structure analysis of medicinal products; Detection and confirmation of signals; Individualised benefit-risk assessment; Effective communication to health professionals and patients in clinical settings.
Causality assessment plays a critical part in the search for better science and safer use of medicines. Although the principles of causality assessment are straightforward, the application of those principles to an individual case is a philosophical as well as a scientific challenge.